Engineered inhalable nanocatalytic therapeutics for Parkinson's disease by inducing mitochondrial autophagy

Mingming Guo, Bowen Li, Guoqing Feng, Xin Su, Xue Wang, Xiaoxuan Han, Manyi Yang, Lipeng Bai, Xiaodong Zhu, Haojun Fan, Bin Zheng

Journal:MATERIALS & DESIGN

IF:8.4

DOI:10.1016/j.matdes.2023.111808

PMID:

Published:2023-03-11

research field:神经科学药学纳米技术治疗学

Abstract

Reactive oxygen species (ROS) - induced oxidative stress damage of dopaminergic neurons is the principal etiology of Parkinson's disease (PD). While most nanoenzymes can catalyze the breakdown of ROS present in the brain, they cannot eradicate the source of ROS production attributed to damaged mitochondria. Herein, we introduce a Co-doped Prussian blue (PB/Co) nanozyme that demonstrates multi-enzyme-like coordinated activity for scavenging present ROS and triggers mitophagy to remove damaged mitochondria. To further augment the brain entry efficiency of PB/Co nanozyme, we encapsulated it in 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 2,3-bis (palmitoyloxy)propyl-2-(trimethylammonio)ethylphosphate (DPPC) cationic liposomes and developed a non-invasive inhalable nanospray ((PB/Co)@DD) that permeates the brain via the olfactory bulb. In the PD mice model, (PB/Co)@DD nanospray induced mitophagy in the striatum to eliminate the ROS production source, preventing excessive ROS-induced sustained damage to dopaminergic neurons and averting the buildup of α-synuclein deposits, thereby ultimately restoring motor function in PD mice. Our research lays the foundation for catalytic therapy to eliminate abnormal mitochondria via the induction of mitophagy in PD mice models and highlights the potential of inhalable nanoenzymes as a non-invasive therapeutic strategy for the treatment of neuroinflammatory diseases.

本文使用的Yeasen产品

购物车
客服
转染试用